Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of KarXT in Youth With Schizophrenia or ASD-Associated Irritability
jRCT2011250071Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of xanomeline in schizophrenia and Autism Spectrum Disorder (ASD) (2 arms), sponsored by Bristol Myers Squibb. Planned start May 2026; status: not yet recruiting.
02
Drugs
xanomeline
03
Conditions
schizophreniaAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on jRCT2011250071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250071.